Clinical Profile and Risk Factors for Severe COVID-19 in Hospitalized Patients from Rio de Janeiro, Brazil: Comparison between the First and Second Pandemic Waves
- PMID: 37048652
- PMCID: PMC10094970
- DOI: 10.3390/jcm12072568
Clinical Profile and Risk Factors for Severe COVID-19 in Hospitalized Patients from Rio de Janeiro, Brazil: Comparison between the First and Second Pandemic Waves
Abstract
Since COVID-19 was declared a pandemic, Brazil has become one of the countries most affected by this disease. A year into the pandemic, a second wave of COVID-19 emerged, with a rapid spread of a new SARS-CoV-2 lineage of concern. Several vaccines have been granted emergency-use authorization, leading to a decrease in mortality and severe cases in many countries. However, the emergence of SARS-CoV-2 variants raises the alert for potential new waves of transmission and an increase in pathogenicity. We compared the demographic and clinical data of critically ill patients infected with COVID-19 hospitalized in Rio de Janeiro during the first and second waves between July 2020 and October 2021. In total, 106 participants were included in this study; among them, 88% had at least one comorbidity, and 37% developed severe disease. Disease severity was associated with older age, pre-existing neurological comorbidities, higher viral load, and dyspnea. Laboratory biomarkers related to white blood cells, coagulation, cellular injury, inflammation, renal, and liver injuries were significantly associated with severe COVID-19. During the second wave of the pandemic, the necessity of invasive respiratory support was higher, and more individuals with COVID-19 developed acute hepatitis, suggesting that the progression of the second wave resulted in an increase in severe cases. These results can contribute to understanding the behavior of the COVID-19 pandemic in Brazil and may be helpful in predicting disease severity, which is a pivotal for guiding clinical care, improving patient outcomes, and defining public policies.
Keywords: COVID-19; epidemic waves; epidemiology; risk factors.
Conflict of interest statement
The authors declare no conflict of interest.
References
-
- World Health Organization Clinical Management of COVID-19: Interim Guidance, 27 May 2020. 2020. [(accessed on 20 December 2022)]. Available online: https://apps.who.int/iris/handle/10665/332196.
-
- Croda J., de Oliveira W.K., Frutuoso R.L., Mandetta L.H., Baia-Da-Silva D.C., Brito-Sousa J.D., Monteiro W.M., Lacerda M.V.G. COVID-19 in Brazil: Advantages of a socialized unified health system and preparation to contain cases. Rev. Soc. Bras. Med. Trop. 2020;53:e20200167. doi: 10.1590/0037-8682-0167-2020. - DOI - PMC - PubMed
LinkOut - more resources
Full Text Sources
Miscellaneous
